Breast cancer cells can lay the groundwork for their own metastasis throughout the body by coaxing cells within lymphatic vessels to send out tumor-welcoming signals, according to a new report.
The researchers at Johns Hopkins University in Baltimore, Maryland, described animal and cell-culture experiments that show increased levels of so-called signaling molecules released by breast cancer cells. These molecules cause lymphatic endothelial cells (LECs) in the lungs and lymph nodes to produce proteins called CCL5 and VEGF. CCL5 attracts tumor cells to the lungs and lymph nodes, and VEGF increases the number of blood vessels and makes them more porous, allowing tumor cells to metastasize and infiltrate the lungs.
In the same report, published in Nature Communications (2014; doi:10.1038/ncomms5715), the researchers say maraviroc, a drug already approved for treating HIV infection, blocked the siren call of CCL5 in tests on animals and cells and prevented tumor spread. Additional experiments using a combination of maraviroc and a drug that blocks the VEGF protein suggest that the treatment duo could be an effective way to prevent metastatic disease in patients with breast cancer.
Because the antiretroviral drug maraviroc has already been approved by the US Food and Drug Administration and has been shown safe for long-term oral use, it could be tested in clinical trials sooner rather than later, said senior author Aleksander Popel, PhD, a professor in the Department of Biomedical Engineering at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.
“It was surprising to find that LECs can play such an active and significant role in tumor spread.” Popel noted. “Conventionally, lymphatic vessels are regarded mainly as passive conduits through which tumor cells spread from the primary tumor and eventually metastasize,” he said. “However, we now know that lymphatic vessels enable metastasis, and other studies also show that they play an important role in whether or not immune cells recognize and attack cancer cells.”
Popel and colleagues traced the influence of tumor signaling on LECs in cell cultures and in mice. Breast cancer cells were bathed in a nutrient-rich liquid, and as the cancer cells grew, the investigators detected secretions of a signaling molecule called interleukin-6 (IL6) in the liquid.
Mice that were injected with the IL6-containing liquid experienced a continual rise in CCL5 levels in blood samples for several weeks. Nine of 10 tumor-bearing mice injected with the IL6-laden liquid developed metastases 5 weeks later. Only 2 of 10 mice exposed to the liquid and given a combination of maraviroc and a VEGF-blocking drug developed metastases.
Because maraviroc blocks the actions of CCL5, it could be delivered, along with standard chemotherapy, right after tumor resection in a bid to prevent any leftover circulating tumor cells from finding a new metastatic niche in the body, Popel said.